Ana sayfa | MS’in Derinliği  | MS Slide Resource

References

1. Matthews WB. Demyelinating disease. In: Weatherall DJ, et al. (eds). Oxford Textbook of Medicine. Oxford: Oxford University Press, 1988;2:21.211-21.218.

2. Silberberg DH. Section eleven / the demyelinating diseases. In: Wyngaarden JB & Smith LH (eds). Cecil Textbook of Medicine. Philadelphia: WB Saunders Company,1988: 2211-2217.

3. Matthews WB. Symptoms and signs. In: Matthews WB (ed). McAlpine's Multiple Sclerosis. 2nd ed. Edinburgh: Churchill Livingstone, 1991:43-105.

4. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13(3):227-231.

5. Arnason BGW. Interferon beta in multiple sclerosis. Neurology 1993;43:641-643.

6. Snell RS (ed). Clinical Anatomy for Medical Students. Boston/Toronto: Little, Brown & Co, 1986.

7. Wheater PR, Burkitt HG, Daniels VG (eds). Functional Histology. Edinburgh: Churchill Livingstone, 1987.

8. Wekerle H, Linington C, Lassmann H, Meyerman R. Cellular immune reetkinligini within the CNS. Trends Neurosci 1986;9:271-277.

9. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today 1994;15(5):218-224.

10. Wisniewski HM, Lossinski AS. Structural and functional aspects of the interaction of inflammatory cells with the blood-brain barrier in experimental brain inflammation. Brain Pathol 1991;1:89-96.

11. Allen I. Pathology of multiple sclerosis. In: Matthews WB (ed). McAlpine's Multiple Sclerosis. 2nd ed. Edinburgh: Churchill Livingstone, 1991:341-378.

12. Prineas JW. The neuropathology of multiple sclerosis. In: Koetsier J (ed). Handbook of Clinical Neurology - Demyelinating Diseases. Amsterdam: Elsevier, 1985;3(47):213-257.

13. Koopmans RA, Li DKB, Oger JJF, et al. The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology 1989;39:959-963.

14. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. (In Press).

15. Lassmann H [ed]. Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Berlin: Springer-Verlag, 1983.

16. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992;18(4):319-334.

17. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979;5:22-31.

18. Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993a;33:137-151.

19. Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 1993;52(3):199-204.

20. Prineas JW, Barnard RO, Revesz T, et al. Multiple sclerosis. Pathology of recurrent lesions. Brain 1993;116:681-693.

21. Brück W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994;35:65-73.

22. Itoyama Y, Webster H deF, Richardson EP Jr, Trapp BD. Schwann cell remyelination of demyelinated axons in spinal cord multiple sclerosis. Ann Neurol 1983;14:339-346.

23. Ghatax NR, Hirano A, Doron Y, et al. Remyelination in multiple sclerosis with peripheral type myelin. Arch Neurol 1973;29:262-267.

24. Matthews WB. Pathophysiology. In: Matthews WB (ed). McAlpine's Multiple Sclerosis. 2nd ed. Edinburgh: Churchill Livingstone, 1991:231-250.

25. Guyton AC (ed). Textbook of Medical Physiology. Philadelphia: WB Saunders Company, 1991.

26. Davis FA, Stefoskí D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-192.

27. Stefoskí D, Davis FA, Fitzsimmons WE, et al. 4-aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-1348.

28. Sears TA, Bostock H. Conduction failure in demyelination. Is it inevitable? Adv Neurol 1981;31:357-375.

29. Isaac C, Li DKB, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988;38:1511-1515.

30. Lumsden H. The neuropathology of multiple sclerosis. In: Handbook of Clinical Neurology. New York: Elsevier, 1970;9:217-309.

31. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1962;25:315-320.

32. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978;4:151-162.

33. Roitt I, Brostoff J, Male D (eds). Immunology. London: Gower medical publishing, 1985.

34. Compston DAS. Immunological aspects of multiple sclerosis. In: Matthews WB (ed). McAlpine's Multiple Sclerosis. 2nd ed. Edinburgh: Churchill Livingstone, 1991:321-339.

35. Olsson T. Immunology of Multiple Sclerosis. Current Opinion on Neurology and Neurosurgery 1992;5:195-202.

36. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol 1991;1:97-105.

37. Lassmann H, Zimprich F, Rössler K, Vass K. Inflammation in the nervous system. Basic mechanisms and immunological concepts. Rev Neurol 1991;147(12):763-781.

38. Wekerle H, Engelhardt B, Risau W, Meyermann R. Interaction of T lymphocytes with cerebral endothelial cells in vitro. Brain Pathol 1991;1:107-114.

39. Wekerle H. Immunopathogenesis of multiple sclerosis. Acta Neurol 1991;13(2):197-204.

40. Raine CS. Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 1991;17:265-274.

41. Wucherpfennig KW, Newcombe J, Li H, et al. T cell receptor V-Vß repertoire and cytokine gene expression in active multiple sclerosis lesions. J Exp Med 1992;175:993-1002.

42. Freedman M, Ruijs T, Selin L, Antel J. Peripheral blood gamma-delta T-cells lyse fresh human brain-derived oligodendrocytes. Ann Neurol 1991;30:794-800.

43. Wucherpfennig KW, Newcombe J, Li H, et al. T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci USA 1992;89:4588-4592.

44. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-454.

45. Esiri MN. Multiple sclerosis: a quantitative and qualitative study of immunoglobulin containing cells in the central nervous system. Neuropathol Appl Neurobiol 1980;6:9-21.

46. Compston DAS, Morgan BP, Campbell AK, et al. Immunocytochemical localisation of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989;15:307-316.

47. Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993;143(2):555-564.

48. Imamura K, Suzumura A, Hayashi F, Marunouchi T. Cytokine production by peripheral blood monocytes /macrophages in multiple sclerosis patients. Acta Neurol Scand 1993;87(4):281-285.

49. Li H, Newcombe J, Groome NP, Cuzner ML. Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques. Neuropathol Appl Neurobiol 1993;19(3):214-223.

50. Lassmann H, Schmied M, Vass K, Hickey W. Bone marrow derived elements and resident microglia in brain inflammation. Glia 1993;7(1): 19-24.

51. Panitch HS, Bever CT. Clinical trials of interferons in multiple sclerosis. What have we learned? J Neuroimmunol 1993;46:155-164.

52. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987;37:1097-1102.

53. Panitch HS. Interferons in multiple sclerosis. A review of the evidence. Drugs 1992;44(6):946-962.

54. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-346.

55. Vass K, Heininger K, Schafer B, Linnington C, Lassmann H. Interferon gamma potentiates antibody-mediated demyelination in vivo. Ann Neurol 1992;32:198-206.

56. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993;43:655-661.

57. Sharief MK, Hentges R, Ciardi M, Thompson EJ. In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood- brain barrier impairment in patients with active multiple sclerosis. J Neurol 1993;240(1):46-50.

58. Ebers GC. Treatment of multiple sclerosis. Lancet 1994;343:275-278.

59. Seitelberger F, Jellinger K, Tschabitscher H. Zur genese der akuten entmerkungsenzephelitis. Wien Klin WSchr 1958;70:453-459.

60. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: A critical overview. Can J Neurol Sci 1993;20(1):17-29.

Bu sayfadaki bilginin en son güncellendiği/doğrulandığı tarih:

11/09/2001

Ana sayfa | Bağlantılar | Kayıt ve geri bildirim | Sözlükçe | Arama motoru ve site haritası | Yerel Bilgiler | Yardım| Bir arkadaşa söyleyin | Sorumluluk almama | Basın Bilgileri | Schering